RxDoctor Payments Data

Erwin Nepomuceno, APRN

Family · San Antonio, TXNPI 1700504909

Payments from drug & device makers

$1,549in general payments, 2019–2025

Across 28 payments — averaging $55.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Axsome Therapeutics, Inc.$125
  • Lilly USA, LLC$99
  • Insulet Corporation$87
  • Amgen$49
  • Novo Nordisk$41
  • plus $128 from 5 others

What the payments were for

  • Travel & lodging$71146%
  • Food & beverage$83854%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,549 in reported general payments places this provider in the 75th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$35,431
Medicare patients
103
Services billed
637

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide102$180,805
MounjaroTirzepatide106$174,693
TrulicityDulaglutide47$64,082
JardianceEmpagliflozin42$63,231
Tresiba Flextouch U-200Insulin Degludec29$27,077
Tresiba Flextouch U-100Insulin Degludec36$23,620
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/711$23,344
JanuviaSitagliptin Phosphate16$22,590
FarxigaDapagliflozin Propanediol19$18,268
Fiasp FlextouchInsulin Aspart (Niacinamide)16$16,003
Nano 2nd Gen Pen NeedlePen Needle, Diabetic73$11,797
Novolog FlexpenInsulin Aspart50$9,532
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$9,326
Humalog Kwikpen U-100Insulin Lispro30$8,808
Lantus SolostarInsulin Glargine,hum.Rec.Anlog65$7,918

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Humalog$99$247,975177 claims
Novo NordiskOzempic$41$180,805102 claims
Boehringer IngelheimJardiance$27$63,23142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 15,456 family providers in Texas.

Other family in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →